• China currently commands approximately 90% of rare earth metals, alloys, and permanent magnets, along with 85% of the world’s rare earth oxides
• This dominance has seen Beijing demonstrate a willingness to leverage it in pursuit of political objectives
• Countries have resorted to looking elsewhere for the supply of rare earths, and Ucore is building to satisfy that demand in North America
• Its recent announcement of a $75 million investment in CapEx over the next four years reflects the company’s understanding of the North American REE market and the value that the investment will create for its shareholders

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company with a vision and plan to become a leading advanced technology company, providing best-in-class metal separation products and services to the mining and mineral extraction industry, is doubling down on its North American operations, in light of a gradual but important shift away from Beijing’s influence over the global rare earth industry.

The move is in response to China’s current global rare earth supply chain dominance, which has seen Beijing demonstrate a willingness to leverage this in pursuit of political objectives. This level of dependence has seen nations such as Japan, the United States, and Europe struggle to afford supplies of rare earths following China’s move to tighten its export quotas and, in return, significantly increase the price of global rare earth imports. For a nation that commands approximately 90% of rare earth metals, alloys, and permanent magnets, along with 85% of the world’s rare earth oxides, it is easy to see how much power China holds, how dependent other nations are on it, and how detrimental this can be both in the immediate and distant futures.

Proactive nations such as Japan have sought to address this dependence by looking elsewhere for the supply of its rare earths. The country has since invested $250 million in Lynas Corporation, an Australian miner, making it the only supplier outside China capable of processing rare earths while accounting for nearly one-third of Japan’s rare earth imports. In the United States, Ucore has stepped up and remains committed to developing a robust North American rare earth elements (“REE”) supply chain built on its revolutionary RapidSX(TM) technology.

Recently, the company announced a $75 million investment in capital expenditures (“CapEx”) over the next four years to establish the region’s first modern technology REE separation and purification facility. Ucore projects that, once done, the facility, located in England Airpark Community in Alexandria, Louisiana, will have a maximum production rate ranging between 5,000 and 7,500 tons per annum of total rare earth oxide (“TREO”). This will help push North American operations, particularly given that there is only one rare earth mine in the United States, located in Mountain Pass, California, which only resumed operations in 2017.

Ucore’s commitment to invest in this market shows confidence in the North American region. In addition, it shows the growing need to shift from dependence on China and the incredible opportunity that comes with it. Most importantly, it reflects Ucore’s understanding of the North American REE market and the value this investment will create for its shareholders.

The recent Secured Credit Facility Agreement with Orca Holdings, LLC of up to $1 million further accentuates the move. The proceeds from this facility will be channeled towards trials at the company’s RapidSX(TM) REE Commercial Demonstration Plant in Kingston, Ontario, ultimately helping refine this transformative commercial-ready technology for separating and purifying critical metals.

The global rare earth market is witnessing a supply chain shift from China to different global players, including the United States. So far, China’s share of global mining production has dipped from 97.7% in 2010 to 62.9% in 2019, with global rare earth reserves falling from 50% to 36.7% over the same period. Ucore is well-positioned to take advantage of, and accelerate this shift in China’s dependence and dominance, potentially making North America a leader in this segment. Its investment in this sector shows the company’s optimism in the industry’s performance and its management’s confidence in the steps the company is taking to achieve its vision.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Lexaria recently reported that dosing of the targeted 36 volunteers in its human clinical oral nicotine study, NIC-H22-1, had been completed
• The company hopes to demonstrate that its DehydraTECH(TM)-processed nicotine absorbs more quickly and more efficiently into the human bloodstream than leading oral nicotine brands
• Through previous animal testing, Lexaria showed that DehydraTECH-nicotine was up to 10x to 20x faster in delivering comparable levels of nicotine and delivered up to 6-fold higher levels of nicotine into blood plasma than concentration-matched controls
• If the findings from the human study replicate a similarly improved performance, Lexaria believes this could facilitate a more satisfying oral nicotine experience than any leading brands sold around the world today
• Success could result in an important commercial relationship developing in 2023, according to CEO Chris Bunka

Lexaria Bioscience (NASDAQ), a global innovator in drug delivery platforms, recently announced that the dosing of the targeted 36 subjects in its human clinical oral nicotine study NIC-H22-1 had been completed. In the meantime, the company has already commenced sample and data analysis and expects to report the findings as soon as possible (https://ibn.fm/7bhFu).

NIC-H22-1 is a human pharmacokinetic randomized, double-blinded, cross-over study that involved 36 human volunteers that are current cigarette smokers. Each participant visited the laboratory for dosing three times over several weeks, and during each visit, only one oral nicotine pouch was administered: Lexaria’s DehydraTECH(TM)-processed purified nicotine, On!(TM) brand manufactured by Altria, or Zyn(TM) brand manufactured by Swedish Match. Dosing began in December 2022 (https://ibn.fm/G4CAT).

“We hope to demonstrate that the Lexaria DehydraTECH-processed nicotine absorbs more quickly and more efficiently into the human bloodstream than the world’s leading oral nicotine brand, Zyn(TM), or America’s third leading brand, On!(TM). If we are successful, we feel this will be a major step towards adoption of our technology into a consumer product, which could result in an important commercial relationship developing in 2023,” Lexaria CEO Chris Bunka wrote in the January 2023 annual letter to stakeholders (https://ibn.fm/3Y7WF).

The study results from years of work as Lexaria sought – and continues to seek – a safe alternative to vaping or cigarette smoking, methods of nicotine intake that pose significant dangers to the health of smokers. Data from the World Health Organization (“WHO”) shows that over seven million people die each year due to direct tobacco use, while about 1.2 million non-smokers die because of exposure to second-hand smoke (https://ibn.fm/OOdMg). And while vapes or e-cigarettes were developed as less harmful alternatives to conventional cigarettes (“c-cigarettes”) because they do not contain combustible tobacco (https://ibn.fm/y5Mj8), NIH-funded studies show that long-term use of e-cigarettes or vaping products can significantly affect the function of blood vessels, increasing the risk of cardiovascular disease (https://ibn.fm/eFnSx).

Over the years, oral nicotine pouches entered the market as companies sought to reduce the societal impact of tobacco globally, and their uptake has been on the up since. According to a 2023 report, the global nicotine pouches market is projected to grow from $4.69 billion in 2022 to $11.91 billion in 2029, representing a CAGR of 13.4% (https://ibn.fm/CR5KW). But despite this projected growth, nicotine pouches have been shown to deliver lower nicotine levels to the blood than with cigarettes, with the time taken to reach peak levels being slower too (https://ibn.fm/ypgdX).

A reluctance by industry to embrace modern technology – has contributed to the failure of older, slow-acting traditional nicotine products to woo smokers; especially considering that in 2020, cigarettes accounted for 84.1% of the retail value sales of all nicotine products, down from 88.9% in 2017 (https://ibn.fm/SyWUk). Given that the global nicotine market is worth roughly $1 Trillion per year, each percentage point of sales represents about $10 billion in revenue. However, Lexaria believes its fast-acting technology – which decreases wait times from as long as an hour to just 3-6 minutes in animal testing – points to a possible seismic shift if improved DehydraTECH nicotine pouches hit the market.

Through animal testing, Lexaria showed that DehydraTECH-nicotine was up to 10x to 20x faster in delivering comparable levels of nicotine into the bloodstream than the peak of concentration-matched controls. The technology also went on to far exceed their total delivery; in particular, it delivered up to 6-fold higher nicotine levels into blood plasma (https://ibn.fm/aSrL6). If the findings from the human study replicate similarly improved performance, Lexaria believes this could facilitate a more satisfying oral nicotine experience than any leading brands sold around the world today.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• George Soros recently warned on the effects of global warming, stating that the potential melting of the Greenland ice sheet could threaten the future of survival
• GeoSolar Technologies has looked to deliver on the technological advances needed to address climate change, through the development of its proprietary Smart Green(TM) Home system
• The residential energy solution seeks to harness solar and geothermal energy in a bid to slash household emissions – whilst simultaneously reducing household utility bills

Billionaire investor, George Soros is well renowned for being outspoken about causes he is passionate for; most recently, his target has been centered around the environment. Earlier this year, Soros addressed the Munich Security Conference, during which he expounded on the dangers posed by the melting of the Greenland ice sheet, an event which he stated, “pose[d] a threat to the survival of our civilization.” Although Soros used the occasion to back the idea of using experimental geo technologies to shield the Arctic from melting, as well as an overhaul of international finance to address the challenge ahead, his speech laid out the stark necessity for new technologies to be developed to confront the increasingly fraught environmental challenges posed by global warming.

GeoSolar Technologies (“GST”), a Colorado-based climate technology company pioneering an approach into clean energy solutions for households, has centered its corporate mission around doing exactly that. The company has pioneered the creation of its proprietary Smart Green(TM) Home system technological solution, designed to address the residential energy use which drives as much as 20 percent of greenhouse gas (“GHG”) emissions in the United States (https://ibn.fm/pWdTU).

Putting that figure into perspective – if the U.S. housing sector’s emissions were to be considered as a country, that country would represent the world’s sixth largest GHG emitter, comparable to the entirety of Brazil’s emissions and ranking significantly higher than those of Germany. Perhaps more ominously, by 2025 the United States will add an estimated 70-129 million residents and 62-105 million new homes, further illustrating the urgent need to reduce emissions across the U.S. housing sector.

In its bid to both, address U.S. household emissions as well as transform every aspect of the living experience for the better, GeoSolar’s proprietary technology seeks to harness both, the power of the sun and earth to fully electrify homes. From solar panels on roofs and geothermal heat pumps which harness heat emanating from the earth’s core, through to advanced CERV 2 air purification systems designed to manage indoor air quality in an efficient and intelligent manner, the Smart Green(TM) system has been designed to dramatically increase the energy efficiency of a conventional household. Ultimately, the technology will seek to void the need for a home to depend on carbon-powered utilities or face increasingly exorbitant energy costs subject to volatile fossil fuel commodity prices (https://ibn.fm/TujRM).

Residential solar PV systems have been shown to reduce an average home’s carbon emissions by 1.3 to 1.6 tonnes per year – the equivalent to the emissions which can come from using 536 gallons of fuel or charging 607,904 smartphones. In fact, a standard solar PV system can help a household to avoid as much as 39 tons of carbon dioxide over the course of its 30-year lifespan, the equivalent environmental impact akin to planting and growing 2,365 tree saplings over a decade (https://ibn.fm/NXsjI). GeoSolar’s Smart Green(TM) Home system has sought to take the technology’s potential one step further, complementing its solar panels with geothermal heat pumps designed to provide households with a reliable and environmentally friendly energy source 24 hours a day.

GeoSolar Technologies has already successfully installed its revolutionary residential technology in multiple homes across the state of Colorado, with tests revealing that households using the GeoSolar’s system boasted some of the most impressive energy efficiency ratings (https://www.resnet.us/raters/hers-raters/) within the sector. More importantly, GeoSolar’s Smart Green Home energy solution will now also help homeowners to benefit from legislation included within the recently passed Inflation Reduction Act, providing households pursuing renewable energy home solutions with an array of tax credits and fiscal incentives.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• As a natural byproduct of landfills and animal waste, RNG presents a powerful tool for reducing environmental impact: it helps curb carbon emissions, diverts organic waste from landfills and has the potential to revolutionize transportation
• Committed to accelerating the shift of the grid to renewable natural gas (“RNG”), EverGen Infrastructure acquires, develops and manages RNG systems that aim to bring sustainable energy from organic waste into the North American gas grid
• EverGen deploys a growth strategy that is based on a combination of regional expansion that replicates the company’s business model regionally and cross-sector expansion whereby EverGen seeks to capitalize on new renewable opportunities arising in complementary markets like new waste-to-energy and hydrogen infrastructure

With its multidimensional benefits, including the potential to reduce greenhouse gas emissions, reuse waste materials, and power transportation, Renewable Natural Gas (“RNG”) is making headlines in the sustainability space, emerging as a promising solution for tackling the growing environmental challenges. EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), an innovative Canadian developer of the RNG infrastructure platform, works to leverage this clean fuel that 1`boasts multiple positive impacts on the environment.

As a clean, low-carbon fuel derived by collecting biogas from organic waste like animal manure, wastewater and food scraps, it is a compelling solution that can reduce the emission of methane into the atmosphere – a potent greenhouse gas that has more than 25 times the impact of carbon dioxide. Initially, biogas has a methane content between 45% and 65%. It goes through a process that includes removing impurities such as water vapor, carbon dioxide, and trace-level contaminants before it gets converted into RNG (https://ibn.fm/lAtAm). After these steps, biogas has more than 90% methane content. Usually, when RNG is streamed into a gas pipeline, it contains between 96% and 98% of methane (https://ibn.fm/2yCDf). Producing RNG by using half of the methane emission as a byproduct of decomposing organics can achieve as much as half of the pledged methane emissions reduction by 2030 (https://ibn.fm/jzsGY).

As a promising renewable energy source, it can revolutionize transportation and change its carbon footprint forever. For example, in California, RNG used as a transportation fuel has soared 163% over the past five years as heavy-duty trucks – a significant contributor to transportation-related emissions – are transitioning to operate on RNG in a bid to decarbonize the state and deliver cleaner air. RNG from biomethane sourced from landfills, waste facilities, wastewater and agricultural operations can provide an affordable proposition for achieving sustainable practices in medium- and heavy-duty transportation (https://ibn.fm/iuFXH).

But as a versatile renewable source, the benefits of RNG extend beyond just GHG reduction since it is often viewed as one of the most effective solutions to decarbonize waste. With a production that diverts organic waste from landfills, it also holds promise as a waste recycling technology that enables a circular economy, where products and materials are reused, waste and pollution are minimized, and the environment is regenerated. Finally, in producing RNG from waste, nothing seems to go to waste. Digestate, an additional product of anaerobic digestion, can be used as fertilizer.

Boasting an impressive project portfolio and remarkable industry partnerships, EverGen is working to be the leader in a fast-evolving RNG space. Dedicated to operational excellence, this innovative Canadian company has adopted a platform strategy to develop and operate RNG projects designed to equip the gas grid in North America with reliable renewable infrastructure.

The company has deployed what looks like a carefully designed growth strategy that is based on regional expansion, where EverGen seeks to replicate its model regionally by growing through a robust pipeline of projects and partnerships to leverage synergies. Before expanding to B.C., Alberta, and Ontario, EverGen had been making its presence seen in its home province, British Columbia, where it sought to become the leading RNG supplier. This regional expansion into attractive markets is enhanced with an approach that aims to capitalize on expansion across new renewable opportunities by positioning the company to capture value in complementary emerging markets such as new waste-to-energy and hydrogen infrastructure opportunities.

​With renewable sources front and center in the fight against climate change, RNG has emerged as a viable proposition for reducing environmental impact and supporting a circular economy. Moreover, as economies around the world rush to prioritize sustainability, companies like EverGen are set to benefit from expanding markets in terms of geography and new renewable opportunities that arise as the green scene continues to evolve.

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Lexaria’s patented DehydraTECH(TM) technology enhances drug bioavailability, making it useful for a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions
• The company is currently exploring the potential benefits of DehydraTECH related to several molecules including, purified nicotine, CBD, antiviral drugs, human hormones, and PDE5 inhibitors
• Lexaria recently announced the completion of its diabetes animal study DIAB-A22-1 with at least three positive outcomes using DehydraTECH-CBD
• California-based InClin, Inc. has been awarded the contract for clinical research organization services for the expected upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1
• Four new patents have been added to Lexaria’s portfolio, bringing the total to 32 granted patents and more pending worldwide

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is improving how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules through its patented DehydraTECH(TM) technology. DehydraTECH can be used with a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions.

Lexaria is focusing its ongoing research and development efforts on advancing product candidates across several key segments, including nicotine replacement, cannabidiol (“CBD”) for hypertension, diabetes and epilepsy, antivirals, human hormones, and phosphodiesterase type 5 (“PDE5”) inhibitors.

The company recently announced the completion of its diabetes animal study DIAB-A22-1, with at least three positive outcomes, including weight loss in obese diabetic-conditioned animals, with improved triglycerides and cholesterol levels. Lexaria plans to conduct additional investigations to learn what an optimum DehydraTECH-CBD dose related to both weight loss and increased physical activity might be, considering that the higher dose studied may have created sedative-like effects of CBD triggering hypolocomotion, which has been observed upon high systemic exposure (https://ibn.fm/zCd08).

Separately, Lexaria has also announced that California-based InClin, Inc. has been awarded the contract for clinical research organization (“CRO”) services for the expected upcoming Food and Drug Administration (“FDA”)-registered, U.S. Phase 1b Investigational New Drug (“IND”) hypertension study HYPER-H23-1 with its DehydraTECH-CBD.

The study is entitled ‘A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension’. The primary objective of this study will be to evaluate the safety and tolerability in up to 120 hypertensive patients, with secondary objectives of efficacy evaluation in reducing blood pressure and detailed pharmacokinetic testing.

InClin is preparing for the study start-up, and Lexaria is expected to begin with patient dosing as soon as possible after the FDA IND filing and review are complete. The company anticipates filing the IND this summer, with FDA authorization likely to follow within about 60 days – resulting in Phase 1b trial commencement of patient dosing as early as October 2023.

According to a recent press release, InClin’s study start-up services include, but are not limited to, clinical site evaluation and selection, personnel and site training, project management, clinical database design and management, quality assurance support, medical writing, study documentation creation, biostatistics and programming, support vendor coordination, Independent Review Board submissions and more (https://ibn.fm/KqAAL).

At the end of April, Lexaria announced that it had received notification of being awarded or allowed four new patents, bringing the total up to 32 granted or allowed patents and even more pending worldwide. The new patents include the United States, Japan, Australia, and Canada. The patent in the U.S. will be the first for Patent Family #21: Compositions and Methods of Treating Hypertension, which the company believes will be particularly important related to its pursuit of utilizing DehydraTECH-CBD concerning the company’s upcoming FDA IND application (https://ibn.fm/XYAPO).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Web3 Berlin is set to host an annual event on the 10th and 11th of June at the Estrel Congress Center. The conference promises to be an unforgettable experience where attendees can focus on networking, onboarding, and education about Web3, and most importantly, it aims to be the biggest Crypto & NFT event in Europe.

The conference has already established itself as a major event on the Web3 calendar, having signed up more than 80 partners, including leading companies and organizations in the industry, such as Solana, Dash, Ramp, KuCoin, VeChain, Celo or Fantom Foundation.

“We are aiming to create an event accessible to as many people as possible, hence a low ticket price threshold. Inclusivity and onboarding new users is the key – with 7,000 attendees expected, this is an excellent opportunity to reach a highly engaged and relevant audience,” said one of the organizers.

The conference will feature a mix of keynote presentations, panel discussions, and satellite events. The sessions will cover a range of topics from blockchain technology, decentralized finance (“DeFi”), non-fungible tokens (“NFTs”), crypto gaming, and more. The speakers will include some of the brightest minds in the industry, providing attendees with valuable insights into the latest trends, best practices, and innovative ideas in the field.

The conference will also offer a range of networking opportunities, allowing attendees to connect with like-minded individuals, startups, and established companies in the industry. Participants will be able to engage in one-on-one conversations, join roundtable discussions, and attend social events, providing an opportunity to forge new relationships and collaborate with others in the space.

The conference will be an excellent opportunity for attendees to gain knowledge, exchange ideas, and collaborate with the best and brightest minds in the industry. The focus on inclusivity and accessibility means that the conference is an ideal venue for newcomers to the field, as well as seasoned professionals looking to expand their knowledge and network.

Web3 Berlin is not only a great opportunity to learn about the latest trends and innovations in the industry, but it is also a chance to be a part of the decentralized future. With the growing adoption of blockchain technology and the increasing interest in cryptocurrencies, the conference provides a platform for individuals and businesses to explore the potential of Web3 and its impact on the future of finance, technology, and society as a whole.

Tickets for Web3 Berlin are available now on the event’s website, starting from 25,00€ for Standard Tickets and 350,00€ for VIP Access. VIP tickets provide extra perks, such as access to VIP Networking Zones, Food&Drinks Catering, and other limited benefits.

Website – https://berlinweb3.com
Twitter – https://twitter.com/berlinweb3com 

• The equity report noted CISO’s triple-digit Q4 growth in several areas
• “We expect Cerberus to build on its momentum in making headway into larger enterprise customers,” report observes
• Cybersecurity talent shortage landscape could be “highly favorable” to Cerberus

A recent Cantor Fitzgerald equity research report is high on CISO Global (NASDAQ: CISO), formerly Cerberus Cyber Sentinel Corp., a leading provider of global cybersecurity and compliance. Noting that the company is strategically positioned to fill the cybersecurity talent shortage gap, Cantor Research gave CISO an overweight rating and a $2 price target (https://nnw.fm/EP1WX).

“Reiterate overweight and moderating our 12-month price target from $5 to $2 due to volatile trading condition; however, growth fundamentals intact,” the report stated. “We believe the modest multiple is justified or even undervalues CISO given its leadership position at scale in the cybersecurity services space, hyper-growth revenue acceleration, a large and expanding TAM, a favorable macro tailwind on continued talent shortages and an improving financial profile.”

The equity report noted CISO’s significant Q4 growth, including revenue of $14.7 million, up 150.3% year-over-year, ahead of Cantor’s estimate of $13.2 million; security managed services growth of 161.8% year-over-year to $12.4 million at a margin of 61.8%; and growth of professional services totaling 102.6% year-over-year to $2.3 million at a margin of 83.2%.

“Cerberus historically bills customers on a monthly basis; however, the company has been selling larger multiyear enterprise contracts in 2022, resulting in a significant acceleration in deferred revenue,” Cantor reported. “We expect Cerberus to build on its momentum in making headway into larger enterprise customers, and therefore, we anticipate deferred revenue balance to build going forward. Free cash flow was at -$2.8 million, strongly ahead of our estimate at -$5.9 million, driven by a more efficient operating margin of -64.5% (vs. our estimate of -67.8%) on the heels of better cost-optimization measures.”

Cantor also noted that the cybersecurity talent shortage landscape could be “highly favorable” to Cerberus. “Management has pointed out 62% of chief information security officers (‘CISOs’) are expecting to face talent shortfall over the next five years and 95% of CISOs don’t believe the skills shortage gap has improved at all over the last couple of years,” the report observed. “The combination of these industry factors is driving a favorable recurring revenue of 62% on a TTM basis and a new logo retention rate of over 90%.

“Cerberus Cyber Sentinel Corporation is in the process of changing its company’s name to CISO Global Inc. as part of its rebranding effort to better align with its mission to ‘bring cybersecurity professionals together on a global basis,’” Cantor continued. “In summary, we believe team CISO has completed its first year as a public company in a positive note despite the challenging macro environment and volatile trading conditions repeatedly experienced by larger public traded peers, and we envision the growth momentum will carry through into 2023E.”

In addition, the report provided an overview of CISO’s financial metrics/KPIs; acquisitions strategy, including the company’s January 2023 agreement to acquire RAN Security, a secured managed services firm based in Buenos Aires, Argentina; and its healthy deals pipeline as further explanation of the high rating. The report also mentioned the appointment of Kyle Young, recently the company’s director of operations, to interim COO and noted the competitive cybersecurity landscape as part of its thorough review of CISO Global.

CISO is gaining recognition as a leading provider of global cybersecurity and compliance as it rapidly expands by acquiring world-class cybersecurity, secured-managed services and compliance companies. These acquisitions bring top-tier talent to the CISO table, enabling the company to utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations, mitigating continuing and emerging security threats and compliance obligations.

For more information, visit the company’s website at www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

• In September 2022, XESP announced its new business strategy of providing managed digital engagement services through its DE2 platform
• In February 2023, XESP named Peter Hager as its President and CEO
• The company’s digital engagement technology has helped dozens of organizations achieve growth results up to nine-times the industry standard
• XESP is a market disrupter for B2B companies looking for $10M+ in additive growth per year

Electronic Servitor Publication Network (OTCQB: XESP) is a digital engagement company offering a managed service which provides digital activation and engagement solutions to companies that seek to optimize their growth. Its managed service is powered by a proven, proprietary technology – the Digital Engagement Engine(TM). This technology provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action – driving growth.

Electronic Servitor Publication Network’s services are designed to drive growth for both established and developing organizations. Through the optimization of digital interactions within current and new communities, the Digital Engagement Engine(TM) ensures that client content is relevant, reaches the right audience, and connects with the intended person at the right time.

The company calls it ‘Growth as a Service’.

Client implementation is nearly effortless, since the solution is completely managed by the Electronic Servitor Publication Network team. This business model allows clients to focus on their brands, core product offerings, and content creation, while the company manages the technology and outcome.

The company is headquartered in Minneapolis, Minnesota.

Technology

Electronic Servitor Publication Network’s Digital Engagement Engine(TM) utilizes a combination of automation, unique data management, and a modern workflow built on a microservices architecture to achieve greater reach and lift. Using sophisticated data analysis and smart technology, the Digital Engagement Engine(TM) provides companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers and revenue streams.

The Digital Engagement Engine(TM) isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.

Market Outlook

According to a report by ReportLinker.com, an award-winning market research firm, the global customer engagement solutions market was estimated at $19.3 billion in 2022 and is forecast to grow to $32.2 billion by 2027, achieving a CAGR of 10.8% during the forecast period.

The report notes that these engagement solutions are vital to companies seeking to widen their customer bases, reduce customer churn rates and increase customer retention. These perceived benefits of customer engagement solutions are likely to drive their growing adoption around the globe during the forecast period, according to the report.

Management Team

Peter Hager is President and CEO of Electronic Servitor. He joined the company from Pointward Inc., a medtech customer engagement agency that provided solutions to drive market entry, growth, and commercialization for Fortune 500 health care brands and medtech startups. He has founded and managed multiple technology, professional services and medtech organizations throughout his career. Mr. Hager holds a bachelor’s degree from Macalester College in St. Paul, Minnesota, with concentrations in economics and psychology.

Jim Kellogg is CFO of Electronic Servitor. He has served as the principal of J. Kellogg & Company Inc., a business and tax consultant, since 2005. He has provided legal support to clients’ business valuations, business interruption and divorce property valuations. He has worked as a professional tax adviser since 1983. Mr. Kellogg obtained his JD with emphasis on taxation from Western State University College of Law and was certified as a financial planner by the College for Financial Planning in 1990.

Thomas (Denny) Spruce, RPh, is COO of Electronic Servitor. He oversees company infrastructure, regulatory reporting, and strategic partner relationships, among other roles and responsibilities. He joined the company in March 2022 and, since that time, has implemented foundational support processes, developed contractual relationships with service providers, managed financial and regulatory reporting and overseen contract development and management with the legal team. Mr. Spruce obtained a BS in Pharmacy from the University of Arkansas.

For more information, visit the company’s website at www.XESPN.com. 

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• Positive preclinical data was presented for the NPRL2 tumor suppressor gene
• The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models
• Validates ONCOPREX(R) platform’s ability to deliver other tumor suppressor genes to potentially address multiple types of cancer
• ONCOPREX(R) Nanoparticle Delivery System is the novel non-viral platform being used for the company’s lead drug candidate, REQORSA(R) Immunogene Therapy, initially targeting lung cancer

Genprex (NASDAQ: GNPX), A cutting-edge gene therapy company striving to improve the lives of cancer and diabetes patients through the creation of groundbreaking treatments, announced last month that its research collaborators presented positive preclinical data for the NPRL2 gene, which is a tumor suppressor gene. The presentation was given at the 2023 American Association of Cancer Research (“AACR”) annual meeting, which took place from April 14-18, 2023, in Orlando, Florida.

The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models.

Genprex’s ONCOPREX(R) Nanoparticle Delivery System is a novel non-viral approach utilizing lipid nanoparticles to deliver tumor suppressor genes that have been deleted during the course of cancer development. The platform allows for the intravenous delivery of various tumor suppressor genes, and potentially other genes, to achieve a therapeutic effect without the risk of toxicity often associated with viral delivery systems.

“The preclinical data also provide further evidence that the ONCOPREX(R) Nanoparticle Delivery System has the ability to be successful using genes other than the TUSC2 gene that we are already using in clinical trials with REQORSA(R),” said Rodney Varner, President and Chief Executive Officer of Genprex, said (https://ibn.fm/9PtRa). “These compelling outcomes give us further confidence in the potentially broad-based application of our non-viral delivery system, which may provide a multitude of potential pipeline opportunities in the future.”

The company’s cancer-fighting technologies may provide new treatment options for large cancer patient populations, such as those with lung cancer.

The company’s oncology pipeline aims to reprogram the course of cancer. Genprex is evaluating its proprietary, non-viral ONCOPREX(R) delivery system, which is believed to be the first systemic gene therapy delivery platform used for cancer in humans, in its REQORSA clinical programs.

“We are pleased to have these positive data that support the therapeutic potential of our non-viral delivery system, which is being used in our current REQORSA(R) clinical oncology programs, presented before some of the world’s leading cancer researchers,” Varner also said. “The use of the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 tumor suppressor gene positions Genprex to expand our clinical pipeline with a new drug candidate.”

In addition to oncology, Genprex is also working on therapies for diabetes, another large patient population with limited treatment options. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 and MafA genes to the pancreas. The candidates in this pipeline have shown in preclinical studies in mice and non-human primates, the potential to stabilize glucose levels and reduce insulin requirements. Genprex’s R&D pipeline for diabetes includes its preclinical candidates, GPX-002 for Type 1 diabetes and GPX-003 for Type 2 diabetes.

Even with certain advancements in treatment, the quality of life remains highly compromised for many with diabetes. Diabetes gene therapies like those being developed by Genprex could hold the potential to provide long-term effectiveness and completely change the course of the disease – enhancing the quality of life for those living with the disease.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Ucore has set out to capitalize on critical mid-market separation of REE through its transformative RapidSX(TM) technology in a bid to address China’s dominance in the rare oxide market
• The company is confident in its approach and has even committed to investing $75 million in CapEx over the next four years to establish North America’s first modern REE separation and purification facility

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a critical metals (“CM”) separation technology company, understands the potential of the rare oxide market and the stake that China currently holds. According to CEO Pat Ryan, this industry is expected to reach $32 billion by the decade’s end. However, with China controlling 90% of this sector, there has been a push by other countries to cut down dependence and seek out alternatives which, in turn, do away with the risks associated with China’s dominance (https://ibn.fm/WdTPC).

Ucore has stepped up, ultimately playing an integral role in establishing a comprehensive North American critical metals supply chain. Through its transformative technology, RapidSX(TM), the company has been able to capitalize on critical mid-market separation of rare earth elements (“REE”) or its lack thereof. In addition, having streamlined its process of arranging work relationships upstream and dealing with downstream customers, the company has managed to carve out a decent market share for itself, with the goal of taking up 20% of the ex-China rare oxide market in the coming years (https://ibn.fm/BRJu9).

The company is confident in its approach and has even committed to investing $75 million in capital expenditure (“CapEx”) over the next four years to establish North America’s first modern REE separation and purification facility. Located in England Airpark Community in Alexandria, Louisiana, this facility will create at least 100 family-wage paying jobs and improve business opportunities for the area (https://ibn.fm/SFRXK). The investment will build on the $10 million already invested in Ucore’s demonstration plant in Kingston, Ontario, with additional plans to engineer a second and third commercial plant to handle all the expected capacity.

Ucore is positioning itself to fulfill North America’s unmet REE needs through commercial production plants. It is doing what its competitors have not, thereby defining the industry and positioning itself as an undisputed market leader. As it continues to carve out its market share, Ucore is placing North America on the map, defining its REE self-reliance, and creating employment and business opportunities while at it.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF